Bourre L - Search Results

1

Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. Guo J, et al. Among authors: bourre l. Biotechnol Adv. 2011 Jul-Aug;29(4):402-17. doi: 10.1016/j.biotechadv.2011.03.003. Epub 2011 Mar 22. Biotechnol Adv. 2011. PMID: 21435387 Review.

2

Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models.

O'Neill MJ, Bourre L, Melgar S, O'Driscoll CM. O'Neill MJ, et al. Among authors: bourre l. Drug Discov Today. 2011 Mar;16(5-6):203-18. doi: 10.1016/j.drudis.2011.01.003. Epub 2011 Jan 22. Drug Discov Today. 2011. PMID: 21262379 Review.

3

Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system.

McCarthy J, O'Neill MJ, Bourre L, Walsh D, Quinlan A, Hurley G, Ogier J, Shanahan F, Melgar S, Darcy R, O'Driscoll CM. McCarthy J, et al. Among authors: bourre l. J Control Release. 2013 May 28;168(1):28-34. doi: 10.1016/j.jconrel.2013.03.004. Epub 2013 Mar 14. J Control Release. 2013. PMID: 23500058

4

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model.

Martin GH, Gonon A, Martin-Jeantet P, Renart-Depontieu F, Biesova Z, Cifuentes A, Mukherjee A, Thisted T, Doerner A, Campbell DO, Bourré L, van der Horst EH, Rezza A, Thiam K. Martin GH, et al. Among authors: bourre l. Front Immunol. 2024 Feb 7;15:1357716. doi: 10.3389/fimmu.2024.1357716. eCollection 2024. Front Immunol. 2024. PMID: 38384461 Free PMC article.

5

Humanized Mouse Models for Immuno-oncology Drug Discovery.

Kumari R, Feuer G, Bourré L. Kumari R, et al. Among authors: bourre l. Curr Protoc. 2023 Aug;3(8):e852. doi: 10.1002/cpz1.852. Curr Protoc. 2023. PMID: 37552031

6

A DNA telomerase vaccine for canine cancer immunotherapy.

Thalmensi J, Pliquet E, Liard C, Chamel G, Kreuz C, Bestetti T, Escande M, Kostrzak A, Pailhes-Jimenez AS, Bourges E, Julithe M, Bourre L, Keravel O, Clayette P, Huet T, Wain-Hobson S, Langlade-Demoyen P. Thalmensi J, et al. Among authors: bourre l. Oncotarget. 2019 May 21;10(36):3361-3372. doi: 10.18632/oncotarget.26927. eCollection 2019 May 21. Oncotarget. 2019. PMID: 31164958 Free PMC article.

7

Myc target miRs and liver cancer: small molecules to get Myc sick.

Buendia MA, Bourre L, Cairo S. Buendia MA, et al. Among authors: bourre l. Gastroenterology. 2012 Feb;142(2):214-8. doi: 10.1053/j.gastro.2011.12.023. Epub 2011 Dec 16. Gastroenterology. 2012. PMID: 22178210 Review. No abstract available.

8

Effective photoinactivation of Gram-positive and Gram-negative bacterial strains using an HIV-1 Tat peptide-porphyrin conjugate.

Bourré L, Giuntini F, Eggleston IM, Mosse CA, Macrobert AJ, Wilson M. Bourré L, et al. Photochem Photobiol Sci. 2010 Dec;9(12):1613-20. doi: 10.1039/c0pp00146e. Epub 2010 Oct 8. Photochem Photobiol Sci. 2010. PMID: 20931134

9

Improved peptide prodrugs of 5-ALA for PDT: rationalization of cellular accumulation and protoporphyrin IX production by direct determination of cellular prodrug uptake and prodrug metabolization.

Giuntini F, Bourré L, MacRobert AJ, Wilson M, Eggleston IM. Giuntini F, et al. Among authors: bourre l. J Med Chem. 2009 Jul 9;52(13):4026-37. doi: 10.1021/jm900224r. J Med Chem. 2009. PMID: 19492812

10

Protoporphyrin IX enhancement by 5-aminolaevulinic acid peptide derivatives and the effect of RNA silencing on intracellular metabolism.

Bourré L, Giuntini F, Eggleston IM, Wilson M, MacRobert AJ. Bourré L, et al. Br J Cancer. 2009 Mar 10;100(5):723-31. doi: 10.1038/sj.bjc.6604928. Epub 2009 Feb 24. Br J Cancer. 2009. PMID: 19240715 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page